Moberg Pharma Q1 revenue rises, losses narrow on Nordic market share gains

Moberg Pharma AB (publ)

12/05/2026 07:11

Overview

Sweden specialty pharma's Q1 net revenue rose yr/yr, losses narrowed across key metrics

Company expanded Karo Healthcare partnership with exclusive license for APAC markets

Approval of additional terbinafine supplier ensures stable supply for global expansion

Outlook

Company says launch timing in new markets depends on regulatory approvals and market conditions

Moberg Pharma may not be able to use Lamisil brand in all new markets

Company is preparing for launches in additional countries as regulatory approvals progress

Result Drivers

NORDIC MARKET SHARE GAINS - Co said Terclara achieved higher market share in Sweden and Norway, with significant yr/yr increases in both value and unit sales

SUPPLY CHAIN STRENGTHENED - Approval of an additional terbinafine supplier ensures stable and scalable access to active substance for global expansion

PARTNERSHIP-LED EXPANSION - Expanded agreement with Karo Healthcare enables entry into APAC markets without building own infrastructure, reducing risk

Company press release: ID:nWkr2wQSGl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-SEK 0.03
Q1 Net Income
-SEK 1.30 mln
Q1 EBIT
-SEK 1.90 mln
Q1 EBITDA
-SEK 1.50 mln


Analyst Coverage

Wall Street's median 12-month price target for Moberg Pharma AB (publ) is SEK13.00, about 18.2% above its May 11 closing price of SEK11.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)